TEST FORMS – introduction

These test forms is an overview of the data needed for submission of the WHO GFN EQAS results into the webtool.

#### **TEST FORM *– Salmonella***

Which method did you use for antimicrobial susceptibility testing of *Salmonella* in this EQAS?

 [ ]  MIC – microbroth dilution

 [ ]  MIC – macro dilution (tubes)

 [ ]  MIC – agar dilution

 [ ]  E-test

 [ ]  Disk diffusion

 [ ]  Tablets – Neo Sensitabs, Rosco

Which standard(s)/guideline(s) did you use when performing AST?

 [ ]  CLSI

 [ ]  EUCAST

 [ ]  ISO 20776-1:2006

 [ ]  TREK

 [ ]  Other

Which incubation conditions did you use?      °C/     h

#### Comments or additional information:      **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.1\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.2\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.3\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.4\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.5\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.6\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.7\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (mg/L) | S / I / R |
| WHO S-19.8\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MERO  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfamethoxazole, SMX |       |       |       |
| Sulfamethoxazole-trimethoprim, SXT |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (FOT), ceftazidime (TAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |
| --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain an ESBL-, AmpC, or carbapenemase-phenotype?[ ]  Yes [ ]  NoPlease select the detected ESBL-phenotype (see guideline in the EQAS protocol) [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype |
|
|
|

Comments:

#### **TEST FORM – *E. coli* reference strain**

Susceptibility testing of *E. coli* reference strain ATCC 25922

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Zone diameter (mm) or MIC-value (mg/L) |
| *E. coli* ATCC 25922 | Ampicillin, AMP |       |
| Cefotaxime, FOT |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftriaxone, CRO |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO  |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX |       |
| Sulfamethoxazole-trimethoprim, SXT |       |
| Tetracycline, TET |       |
| Trimethoprim, TMP |       |